Data gathered: December 28
Alternative Data for Royalty Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Google Trends | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,314 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 96 | Sign up | Sign up | Sign up |
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
| Price | $25.54 |
| Target Price | Sign up |
| Volume | 2,040,000 |
| Market Cap | $15B |
| Year Range | $24.28 - $29.03 |
| Dividend Yield | 3.37% |
| PE Ratio | 10 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Jim Cramer on Royalty Pharma plc (RPRX): ‘Disappointing Stock, Man, I Can’t Believe It’December 26 - Yahoo |
 |
Royalty Pharma (NASDAQ:RPRX) Raised to “Strong-Buy” at TD CowenDecember 25 - ETF Daily News |
 |
Royalty Pharma plc (NASDAQ:RPRX) is favoured by institutional owners who hold 72% of the companyDecember 23 - Yahoo |
|
Jim Cramer Calls Royalty Pharma (RPRX) ‘Disappointing’ But Recommends Holding – ‘I Want You To Stick With It’December 23 - Yahoo |
|
Wilmington Savings Fund Society FSB Buys Shares of 2,170 Royalty Pharma plc (NASDAQ:RPRX)December 22 - ETF Daily News |
|
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Sanctuary Advisors LLCDecember 22 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 565M | -171M | 736M | 544M | 735M | 0.000 |
| Q2 '24 | 537M | 267M | 270M | 102M | 270M | 0.960 |
| Q1 '24 | 568M | 642M | -74M | 4.8M | -74M | 0.980 |
| Q4 '23 | 596M | -26M | 623M | 494M | 613M | 1.150 |
| Q3 '23 | 536M | 334M | 202M | 72M | 168M | 0.790 |
Insider Transactions View All
| RIGGS RORY B filed to sell 20,099 shares at $27.5. January 4 '24 |
| RIGGS RORY B filed to sell 55,801 shares at $27.8. January 4 '24 |
| RIGGS RORY B filed to sell 254,899 shares at $28.5. January 4 '24 |
| Giuliani Mario Germano filed to sell 2,477,520 shares at $28. January 3 '24 |
| Giuliani Mario Germano filed to sell 2,543,323 shares at $28.2. December 29 '23 |
Similar companies
Read more about Royalty Pharma (RPRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Royalty Pharma?
The Market Cap of Royalty Pharma is $15B.
What is Royalty Pharma's PE Ratio?
As of today, Royalty Pharma's PE (Price to Earnings) ratio is 10.
What is the current stock price of Royalty Pharma?
Currently, the price of one share of Royalty Pharma stock is $25.54.
How can I analyze the RPRX stock price chart for investment decisions?
The RPRX stock price chart above provides a comprehensive visual representation of Royalty Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Royalty Pharma shares. Our platform offers an up-to-date RPRX stock price chart, along with technical data analysis and alternative data insights.
Does RPRX offer dividends to its shareholders?
Yes, Royalty Pharma (RPRX) offers dividends to its shareholders, with a dividend yield of 3.37%. This dividend yield represents Royalty Pharma's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Royalty Pharma in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Royalty Pharma?
Some of the similar stocks of Royalty Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.